Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy

L. A. Kroger, Gerald L Denardo, P. H. Gumerlock, Yi Xiong Cheng Yi Xiong, M. D. Winthrop, Bao Shi Xu Bao Shi, Philip Mack, T. Leshchinsky, S. J. Denardo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. Apoptosis has been suggested to be a major mechanism for cell death from continuous low-dose rate radiation from radioimmunotherapy. The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67CU-2IT-BAT-Lym-1 RIT. In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses. The Raji model mirrors human lymphomas that have mutant p53 and increased BCL2 expression. Untreated athymic BALB/c nu/nu mice and mice treated with 400 μg Lym-1, or 335-500 μCi 67Cu on less than 400 μg Lym-1 antibody, were observed for toxicity and response over 84 days. Subgroups of 4-5 mice were sacrificed at 3, 6 and 24 h after therapy so that tumors could be examined for poly(ADP-ribose) polymerase (PARP) and DNA ladder evidence for apoptosis and for BCL2, p53, p21, GADD45, TGF-Β1 and c-MYC gene and protein expression. Untreated tumors had little evidence of apoptosis and Lym-1 had no effect on apoptosis or gene expression. 67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50% with tolerable toxicity, and 29% of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy. Apoptosis was greatly increased in the RIT treated Raji xenografts as evidenced by cleavage of PARP to the characteristic 85 kD fragment at 3 and 6 h and by the DNA cleavage pattern. BCL2 gene and protein expression were substantially decreased at 3 and 24 h, respectively, after 67Cu-2IT-BA-Lym-1 RIT despite only modest cumulated radiation doses (56 cGy at 3 h). Evidence for apoptosis preceded tumor regression by 4-6 days. In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms.

Original languageEnglish (US)
Pages (from-to)213-225
Number of pages13
JournalCancer Biotherapy and Radiopharmaceuticals
Volume16
Issue number3
StatePublished - 2001

Fingerprint

Radioimmunotherapy
Heterografts
Lymphoma
Radiation
Apoptosis
Gene Expression
Proteins
Neoplasms
Poly(ADP-ribose) Polymerases
Proto-Oncogene Proteins c-bcl-2
copper-67-2IT-BAT-Lym-1
DNA Cleavage
Cell Death
Therapeutics
Clinical Trials

Keywords

  • Antibody
  • Apoptosis
  • Bcl2
  • Low-dose rate radiation
  • p21
  • p53
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. / Kroger, L. A.; Denardo, Gerald L; Gumerlock, P. H.; Cheng Yi Xiong, Yi Xiong; Winthrop, M. D.; Xu Bao Shi, Bao Shi; Mack, Philip; Leshchinsky, T.; Denardo, S. J.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 16, No. 3, 2001, p. 213-225.

Research output: Contribution to journalArticle

Kroger, LA, Denardo, GL, Gumerlock, PH, Cheng Yi Xiong, YX, Winthrop, MD, Xu Bao Shi, BS, Mack, P, Leshchinsky, T & Denardo, SJ 2001, 'Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy', Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 213-225.
Kroger, L. A. ; Denardo, Gerald L ; Gumerlock, P. H. ; Cheng Yi Xiong, Yi Xiong ; Winthrop, M. D. ; Xu Bao Shi, Bao Shi ; Mack, Philip ; Leshchinsky, T. ; Denardo, S. J. / Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. In: Cancer Biotherapy and Radiopharmaceuticals. 2001 ; Vol. 16, No. 3. pp. 213-225.
@article{b37081a03a7949f99bfa86f42b3d8bc2,
title = "Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy",
abstract = "Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. Apoptosis has been suggested to be a major mechanism for cell death from continuous low-dose rate radiation from radioimmunotherapy. The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67CU-2IT-BAT-Lym-1 RIT. In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses. The Raji model mirrors human lymphomas that have mutant p53 and increased BCL2 expression. Untreated athymic BALB/c nu/nu mice and mice treated with 400 μg Lym-1, or 335-500 μCi 67Cu on less than 400 μg Lym-1 antibody, were observed for toxicity and response over 84 days. Subgroups of 4-5 mice were sacrificed at 3, 6 and 24 h after therapy so that tumors could be examined for poly(ADP-ribose) polymerase (PARP) and DNA ladder evidence for apoptosis and for BCL2, p53, p21, GADD45, TGF-Β1 and c-MYC gene and protein expression. Untreated tumors had little evidence of apoptosis and Lym-1 had no effect on apoptosis or gene expression. 67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50{\%} with tolerable toxicity, and 29{\%} of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy. Apoptosis was greatly increased in the RIT treated Raji xenografts as evidenced by cleavage of PARP to the characteristic 85 kD fragment at 3 and 6 h and by the DNA cleavage pattern. BCL2 gene and protein expression were substantially decreased at 3 and 24 h, respectively, after 67Cu-2IT-BA-Lym-1 RIT despite only modest cumulated radiation doses (56 cGy at 3 h). Evidence for apoptosis preceded tumor regression by 4-6 days. In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms.",
keywords = "Antibody, Apoptosis, Bcl2, Low-dose rate radiation, p21, p53, Radioimmunotherapy",
author = "Kroger, {L. A.} and Denardo, {Gerald L} and Gumerlock, {P. H.} and {Cheng Yi Xiong}, {Yi Xiong} and Winthrop, {M. D.} and {Xu Bao Shi}, {Bao Shi} and Philip Mack and T. Leshchinsky and Denardo, {S. J.}",
year = "2001",
language = "English (US)",
volume = "16",
pages = "213--225",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy

AU - Kroger, L. A.

AU - Denardo, Gerald L

AU - Gumerlock, P. H.

AU - Cheng Yi Xiong, Yi Xiong

AU - Winthrop, M. D.

AU - Xu Bao Shi, Bao Shi

AU - Mack, Philip

AU - Leshchinsky, T.

AU - Denardo, S. J.

PY - 2001

Y1 - 2001

N2 - Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. Apoptosis has been suggested to be a major mechanism for cell death from continuous low-dose rate radiation from radioimmunotherapy. The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67CU-2IT-BAT-Lym-1 RIT. In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses. The Raji model mirrors human lymphomas that have mutant p53 and increased BCL2 expression. Untreated athymic BALB/c nu/nu mice and mice treated with 400 μg Lym-1, or 335-500 μCi 67Cu on less than 400 μg Lym-1 antibody, were observed for toxicity and response over 84 days. Subgroups of 4-5 mice were sacrificed at 3, 6 and 24 h after therapy so that tumors could be examined for poly(ADP-ribose) polymerase (PARP) and DNA ladder evidence for apoptosis and for BCL2, p53, p21, GADD45, TGF-Β1 and c-MYC gene and protein expression. Untreated tumors had little evidence of apoptosis and Lym-1 had no effect on apoptosis or gene expression. 67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50% with tolerable toxicity, and 29% of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy. Apoptosis was greatly increased in the RIT treated Raji xenografts as evidenced by cleavage of PARP to the characteristic 85 kD fragment at 3 and 6 h and by the DNA cleavage pattern. BCL2 gene and protein expression were substantially decreased at 3 and 24 h, respectively, after 67Cu-2IT-BA-Lym-1 RIT despite only modest cumulated radiation doses (56 cGy at 3 h). Evidence for apoptosis preceded tumor regression by 4-6 days. In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms.

AB - Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. Apoptosis has been suggested to be a major mechanism for cell death from continuous low-dose rate radiation from radioimmunotherapy. The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67CU-2IT-BAT-Lym-1 RIT. In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses. The Raji model mirrors human lymphomas that have mutant p53 and increased BCL2 expression. Untreated athymic BALB/c nu/nu mice and mice treated with 400 μg Lym-1, or 335-500 μCi 67Cu on less than 400 μg Lym-1 antibody, were observed for toxicity and response over 84 days. Subgroups of 4-5 mice were sacrificed at 3, 6 and 24 h after therapy so that tumors could be examined for poly(ADP-ribose) polymerase (PARP) and DNA ladder evidence for apoptosis and for BCL2, p53, p21, GADD45, TGF-Β1 and c-MYC gene and protein expression. Untreated tumors had little evidence of apoptosis and Lym-1 had no effect on apoptosis or gene expression. 67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50% with tolerable toxicity, and 29% of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy. Apoptosis was greatly increased in the RIT treated Raji xenografts as evidenced by cleavage of PARP to the characteristic 85 kD fragment at 3 and 6 h and by the DNA cleavage pattern. BCL2 gene and protein expression were substantially decreased at 3 and 24 h, respectively, after 67Cu-2IT-BA-Lym-1 RIT despite only modest cumulated radiation doses (56 cGy at 3 h). Evidence for apoptosis preceded tumor regression by 4-6 days. In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms.

KW - Antibody

KW - Apoptosis

KW - Bcl2

KW - Low-dose rate radiation

KW - p21

KW - p53

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034953412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034953412&partnerID=8YFLogxK

M3 - Article

C2 - 11471486

AN - SCOPUS:0034953412

VL - 16

SP - 213

EP - 225

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -